Online inquiry

IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7848MR)

This product GTTS-WQ7848MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7848MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4053MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ7188MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7985MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ3174MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ6169MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ11257MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ7205MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW